DE3844046A1 - Pharmaceutical compositions which contain isomers of hydroxylysine or lysine - Google Patents

Pharmaceutical compositions which contain isomers of hydroxylysine or lysine

Info

Publication number
DE3844046A1
DE3844046A1 DE19883844046 DE3844046A DE3844046A1 DE 3844046 A1 DE3844046 A1 DE 3844046A1 DE 19883844046 DE19883844046 DE 19883844046 DE 3844046 A DE3844046 A DE 3844046A DE 3844046 A1 DE3844046 A1 DE 3844046A1
Authority
DE
Germany
Prior art keywords
hydroxylysine
lysine
pharmaceutical compositions
medicament
contain isomers
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
DE19883844046
Other languages
German (de)
Inventor
Wilhelm Dr Hoerrmann
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to DE19883844046 priority Critical patent/DE3844046A1/en
Publication of DE3844046A1 publication Critical patent/DE3844046A1/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The invention relates to pharmaceutical compositions which contain isomers of hydroxylysine or lysine and are intended for the treatment of venous disorders, cardiac disorders and other disorders.

Description

Die Erfindung betrifft ein Arzneimittel, das als Wirksubstanz mindestens ein Isomeres des Hydroxylysins oder Lysins oder deren pharmazeutisch annehmbare Abkömmlinge, gegebenenfalls zusammen mit üblichen Trägern und/oder Hilfsmitteln enthält. Dabei ist zu beachten, daß das Isomere des Hydroxylysins oder Lysins in der L- oder D-Konfiguration vorliegen kann, wobei die L-Konfiguration bevorzugt ist, daß die Hydroxylgruppe sich von beta bis delta an verschiedenen Stellen der Kohlenstoffkette befinden kann, wobei die delta-Position bevorzugt ist und bezüglich der stereoisomeren Stellung der Hydroxylgruppe an einem asymmetrischen Kohlenstoffatom beide Isomere pharmazeutisch von Bedeutung sind.The invention relates to a medicament that acts as an active substance at least one isomer of hydroxylysine or Lysine or its pharmaceutically acceptable derivatives, optionally together with conventional carriers and / or Contains aids. It should be noted that the isomer of hydroxylysine or lysine in the L or D configuration can be present, the L configuration being preferred is that the hydroxyl group is from beta to delta located at different points in the carbon chain can, with the delta position being preferred and with respect the stereoisomeric position of the hydroxyl group on a asymmetric carbon atom both isomers pharmaceutical are important.

Die Wirkung dieser Arzneimittel kann durch die Zugabe von N-Methyl-aminoäthanol und/oder N-Dimethyl-aminoäthanol, z. B. in Form ihrer Säureadditionssalze gesteigert werden. The effect of these drugs can be increased by adding N-methylaminoethanol and / or N-dimethylaminoethanol, e.g. B. in the form of their acid addition salts.  

Die Strukturformeln dieser an sich bekannten Verbindung werden hier nur der Vollständigkeit halber wiedergegeben.The structural formulas of this known compound are only given here for the sake of completeness.

Die genannten Verbindungen sind als solche bekannt und können nach an sich bekannten Verfahren hergestellt werden.The compounds mentioned are known as such and can be prepared by methods known per se will.

Die erfindungsgemäßen Arzneimittel können die Isomere des Hydroxylysins oder Lysins auch in Form von pharmazeutisch verträglichen Abkömmlingen enthalten, besonders solche, die im Körper in die freie Form der Derivate übergehen. Dazu gehören insbesondere Alkalisalze, Erdalkalisalze, Säureadditionssalze, Ester, Amide und Äther von Hydroxylysin oder Lysin und deren N-alkyl-Derivate sowie Oligo- oder Polypeptide davon. The pharmaceuticals according to the invention can the isomers of Hydroxylysins or lysines also in the form of pharmaceutical contain compatible descendants, especially those which go into the free form of derivatives in the body. These include in particular alkali salts, alkaline earth salts, Acid addition salts, esters, amides and ethers of hydroxylysine or lysine and their N-alkyl derivatives and oligo or polypeptides thereof.  

Die erfindungsgemäßen Arzneimittel dienen der Behandlung der nachfolgend aufgeführten Erkrankungen, sei es durch ihre alleinige Gabe oder zur Unterstützung herkömmlicher Therapie. Die herkömmliche Therapie ist in vielen Fällen unbefriedigend, was schon daraus hervorgeht, daß in einer nicht kleinen Zahl von Fällen operative Eingriffe heute noch unumgänglich sind.The medicaments according to the invention are used for treatment of the diseases listed below, be it through given alone or in support of conventional ones Therapy. The conventional therapy is in many cases unsatisfactory, which already results from the fact that in a not a small number of cases of surgery today are still inevitable.

Anwendungsgebiete der erfindungsgemäßen Arzneimittel:
1. Venenerkrankungen: Hierzu gehören vor allem Erweiterungen und entzündliche Veränderungen der Venen, sowie Varicocoelen und Hämorrhoiden, außerdem Hirnsinuserkrankungen und verwandte Krankheitsbilder.
2. Herzerkrankungen: Vor allem Endocarditis und Folgen, sowie Myocarditis und Folgen, wozu bei letzteren vor allem Herzrhythmusstörungen zu nennen sind.
3. Scharlach, Rheumatisches Fieber, Septische Gelenkerkrankungen, Erysipel, Impetigo usw.
4. Prostatitis und Adnexitis.
5. Analfissuren.
6. Zahncaries.
7. Neurologische Erkrankungen, im besonderen solche, die mit Störungen der Motorik und Sensibilität einhergehen.
8. Hernien. Areas of application of the medicaments according to the invention:
1. Venous disorders: These primarily include dilatation and inflammatory changes in the veins, as well as varicocoeles and hemorrhoids, as well as brain sinus disorders and related clinical pictures.
2. Heart diseases: Above all, endocarditis and consequences, as well as myocarditis and consequences, for which the latter mainly include cardiac arrhythmias.
3. Scarlet fever, rheumatic fever, septic joint disease, erysipelas, impetigo, etc.
4. Prostatitis and adnexitis.
5. Anal fissures.
6. Dental caries.
7. Neurological diseases, in particular those that are associated with motor disorders and sensitivity.
8. Hernias.

Das Wirkprinzip in allen oben genannten Fällen liegt in einer durch die erfindungsgemäßen Arzneimittel bewirkten Stärkung von intra- und extrazellulären Fasersystemen.The principle of action in all of the above cases lies in one caused by the medicament according to the invention Strengthening of intra- and extracellular fiber systems.

Die erfindungsgemäßen Arzneimittel werden in grundsätzlich gleicher Weise verabreicht wie die gewöhnlichen Aminosäuren, also bevorzugt peroral oder intravenös, bzw. zentralintravenös. Auch die Zufuhr in Tabletten, Dragees, Injektions- und Infusionslösungen ist die gleiche.The medicinal products according to the invention are in principle administered in the same way as the usual amino acids, therefore preferably orally or intravenously, or central intravenous. Also the supply in tablets, coated tablets, Injection and infusion solutions are the same.

Bei oberflächlichen gut zugänglichen Krankheitsherden kommt auch die örtliche Anwendung als Lösung oder Puder oder Salbe oder dergleichen in Betracht. For superficial, easily accessible foci of disease there is also local use as a solution or powder or ointment or the like.  

Da es sich um untoxische Verbindungen handelt, kann sich die Dosierung in einem weiten Bereich bewegen, wobei man die übliche therapeutische Aminosäure-Dosierung mit 0,01 bis 0,1 g pro kg und Substanz auch hier zugrunde legen kann.Since these are non-toxic compounds, move the dosage in a wide range, whereby one with the usual therapeutic amino acid dosage Again, use 0.01 to 0.1 g per kg and substance can.

Die für alle Aminosäuren geltenden Kontraindikationen sind auch hier zu beachten.The contraindications for all amino acids are also to be considered here.

Die pharmazeutische Herstellung und Verarbeitung erfolgt in allgemein üblicher Weise und berücksichtigt die gesetzlichen Bestimmungen in Hinsicht auf Substanzreinheit, Sterilität, Pyrogenfreiheit usw.The pharmaceutical production and processing takes place in a generally customary manner and takes into account the legal Provisions regarding substance purity, Sterility, freedom from pyrogens, etc.

Claims (6)

1. Arzneimittel, enthaltend als Wirksubstanz mindestens ein Isomeres des Hydroxylysins oder Lysins oder dessen pharmazeutisch annehmbaren Abkömmling, gegebenenfalls zusammen mit üblichen Trägern und/oder Hilfsmitteln.1. Medicament containing at least as active substance an isomer of hydroxylysine or lysine or its pharmaceutically acceptable derivative, if appropriate together with usual carriers and / or aids. 2. Arzneimittel nach Anspruch 1, dadurch gekennzeichnet, daß das Hydroxylysin oder Lysin in der L-Form vorliegt.2. Medicament according to claim 1, characterized in that the hydroxylysine or lysine is in the L form. 3. Arzneimittel nach einem der Ansprüche 1-2, dadurch gekennzeichnet, daß sich die Hydroxylgruppe des Hydroxylysins in delta-Position befindet.3. Medicament according to one of claims 1-2, characterized characterized in that the hydroxyl group of hydroxylysine located in delta position. 4. Arzneimittel nach einem der Ansprüche 1-3, dadurch gekennzeichnet, daß sich die Hydroxylgruppe des Hydroxylysins in einer der beiden isomeren Stellungen alpha oder beta befindet.4. Medicament according to one of claims 1-3, characterized in that the hydroxyl group of hydroxylysine in one of the two isomeric positions alpha or beta. 5. Unterstützung der Wirkung eines Arzneimittels nach den Ansprüchen 1-4 durch die Zufügung von N-Methyl-aminoasthanol und/oder N-Dimethyl-aminoäthanol.5. Support the effect of a drug according to the Claims 1-4 by the addition of N-methyl-aminoasthanol and / or N-dimethylaminoethanol. 6. Unterstützung der Wirkung eines Arzneimittels nach den Ansprüchen 1-5, dadurch gekennzeichnet, daß die zugefügten Substanzen N-Methyl-aminoäthanol und/oder N-Dimethyl-aminoäthanol in Form ihrer Säureadditionssalze vorliegen.6. Support the effect of a drug according to the Claims 1-5, characterized in that the added Substances N-methyl-aminoethanol and / or N-dimethylaminoethanol in the form of its acid addition salts are available.
DE19883844046 1988-12-28 1988-12-28 Pharmaceutical compositions which contain isomers of hydroxylysine or lysine Withdrawn DE3844046A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
DE19883844046 DE3844046A1 (en) 1988-12-28 1988-12-28 Pharmaceutical compositions which contain isomers of hydroxylysine or lysine

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19883844046 DE3844046A1 (en) 1988-12-28 1988-12-28 Pharmaceutical compositions which contain isomers of hydroxylysine or lysine

Publications (1)

Publication Number Publication Date
DE3844046A1 true DE3844046A1 (en) 1990-07-05

Family

ID=6370357

Family Applications (1)

Application Number Title Priority Date Filing Date
DE19883844046 Withdrawn DE3844046A1 (en) 1988-12-28 1988-12-28 Pharmaceutical compositions which contain isomers of hydroxylysine or lysine

Country Status (1)

Country Link
DE (1) DE3844046A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10106852A1 (en) * 2001-02-14 2002-09-05 T Luger Anti-inflammatory compounds

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10106852A1 (en) * 2001-02-14 2002-09-05 T Luger Anti-inflammatory compounds

Similar Documents

Publication Publication Date Title
DE69822665T2 (en) USE OF 9-DESOXY-2 ', 9-ALPHA-METHANO-3-OXA-4,5,6-TRINOR-3,7- (1', 3'-INTERPHENYLENE) -13,14-DIHYDROPROSTAGLANDIN-F1 FOR TREATMENT OF PERIPHERAL VASCULAR DISEASES
DE3784905T2 (en) GAMMA-L-GLUTAMYL-L-CYSTEIN ETHYL ESTER AND MEDICINAL PRODUCTS CONTAINING THIS AS AN ACTIVE AGENT.
DE69713485T2 (en) Medicines for the treatment or prevention of thrombocytopenia
DE2911670A1 (en) MEDICINES FOR THE THERAPEUTIC TREATMENT OF PERIPHERAL VASCULAR DISEASES
DE2903558A1 (en) THERAPEUTIC METHOD OF TREATMENT OF HYPERLIPOPROTEINEMIA AND HYPERLIPIDAEMIA, AND MEDICINAL PRODUCTS FOR ITS PERFORMANCE
DE3709621A1 (en) THERAPEUTIC AGENT
DE69129115T2 (en) NEW METHOD FOR TREATING DEPRESSION
DE69027220T2 (en) COMPOSITION AND METHOD FOR TREATING PAINFUL INFLAMMABLE OR ALLERGIC DISEASES
DE2903579A1 (en) USE OF ACETYL CARNITINE AND OTHER ACYLDER DERIVATIVES OF CARNITINE FOR THE TREATMENT OF HYPERLIPOPROTEINEMIC AND HYPERLIMPIDAEMIA AND MEDICINAL PRODUCTS
EP0185210B1 (en) Use of dipeptide derivatives for the preparation of medicaments for the treatment of sufferers from amyotrophic lateral sclerosis
DE68904358T2 (en) PROSTAGLANDINALOG FOR USE IN MEDICINE.
DE3390116C2 (en) Improved caffeine-containing analgesic and anti-inflammatory agents
DE3686520T2 (en) USE OF SOME ALKANOYL-L-CARNITINES IN THE PRODUCTION OF A MEDICINAL PRODUCT FOR THE THERAPEUTIC TREATMENT OF IDEOPATHIC OR INDUCED PARKINSONISM.
EP0871437B1 (en) Use of boswellic acid for treating brain tumours
DE69829290T2 (en) USE OF ALKANOYLCARNITINE DERIVATIVES FOR THE TREATMENT OF HYPERACTIVITY WITH ATTENTION FAILURES
DE69321585T2 (en) PARRTERAL SOLUTIONS CONTAINING 3-DIALKYLAMINOETHOXYBENZOYLBENZOFURANE
DE69226487T2 (en) Use of furanone derivatives for the prevention or treatment of autoimmune diseases
EP0345247A2 (en) Use of monosubstitute selenium compounds in the preparation of a pharmaceutical, pharmaceutical and preparation thereof
DE2166355C2 (en) Use of d, 1-sobrerol in balm therapy of the respiratory tract
EP0817623B1 (en) Medicaments for the selective treatment of tumour tissues
DE2611976C2 (en) Use of L-pyroglutamyl-L-histidyl-L-prolinamide or its physiologically acceptable salts for the treatment of states of reduced consciousness
DE3619426A1 (en) AGENT FOR INCREASING RESISTANCE TO COLD DISEASES IN PATIENTS WITH RESTRICTED LUNG FUNCTION
DE3525390C2 (en)
DE3744542A1 (en) MEDICINAL PRODUCTS CONTAINING ISOMERS OF HYDROXYLYSINE OR LYSINE
DE68907976T2 (en) Use of a thromboxane A2 receptor antagonist for the manufacture of a medicament for the treatment of pulmonary hypertension caused by protamine-induced neutralization of heparin.

Legal Events

Date Code Title Description
8130 Withdrawal